Dr. Eugene Gu: Changing the World Through Cool Quit

Dr. Eugene Gu

Dr. Eugene Gu

LOS ANGELES, CA, USA, May 28, 2020 /EINPresswire.com/ — When it comes to changing the world in the midst of the coronavirus pandemic, not many have been as effective as Dr. Eugene Gu. Dr. Gu is the CEO and co-founder of Cool Quit, LLC, a smoking cessation telemedicine company that has now turned its attention, infrastructure, and resources to the fight against COVID-19. "It may sound like a platitude by now, but I truly do believe that we are all in this together. That means we must all do what we can whether we are big or small to help each other and the American people during the worst pandemic in modern history."

With new updates to Cool Quit, it seems that Dr. Eugene Gu's stock is on the rise. "We are very happy to announce that we can now offer at-home coronavirus testing kits to patients." Eugene Gu said when talking about the latest telemedicine innovation in his product line. "We have effectively been able to leverage the changing healthcare laws and expansion of telemedicine allowances to get people free telehealthcare and even free home testing kits that are reimbursed by their insurance companies."

Before the at-home coronavirus testing kits were announced, however, Cool Quit had been already putting in the work with free COVID-19 screening, evaluation, and testing for elderly Medicare patients in 42 states including Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Maine, Michigan, Montana, New Hampshire, New Jersey, New York, New Mexico, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Utah, Vermont, Washington, and West Virginia. "It was a huge deal and I am happy to say that thanks to the flexibility of our staff as well as our ability to stay vigilant and nimble, we were able to get testing set up in those locations and even rural underserved areas that needed it the most." Eugene Gu noted. "I think that right now, it is important for us to stand up for those that need help the most, and that means our elderly seniors who are most affected by this pandemic. We also are reaching out to patients with underlying health conditions like obesity, diabetes, hypertension." Eugene Gu continued.

Eugene Gu, it should be noted, is a Stanford trained medical doctor who found his way into the medical testing world. "It was a way for me to do something greater than just seeing patients one on one. I found it to be a way to impact communities in a more positive way." Eugene Gu said. "I found that developing telemedicine tools and health monitoring programs could impact more people at once than my practice ever could."

Eugene Gu is also quick to point out how impressed he is with the doctors within his own organization and their ability to react in times of crisis. "I think it is important that physicians always put their patients first." Eugene Gu noted. "For many of our physicians at Cool Quit, telemedicine is a completely new technology to them." Eugene Gu continues. "But they learned quickly and adapted to the rapidly changing healthcare needs that the worst pandemic in modern history requires. I couldn’t be more proud of their hard work and dedication".

About Eugene Gu

Caroline Hunter
Web Presence, LLC
+1 786-233-8220
email us here
Visit us on social media:

Eugene Gu

Source: EIN Presswire

Voip-Pal CEO Emil Malak explains that we are in a Global War with the Coronavirus

VOIP-PAL Corporate Logo


CEOCFO Magazine logo

In an interview with CEOCFO Magazine, VOIP-PAL CEO and Director Emil Malak discusses the asymptomatic COVID-19, the reopening of states and the airlines


Requiring each passenger to show a current negative test result before boarding will restore confidence in the safety of air travel.”

— Emil Malak

WASHINGTON, DC, US, May 28, 2020 /EINPresswire.com/ — CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today announced an interview and op-ed (https://www.ceocfointerviews.com/voippaloped7052620.html) with Emil Malak, CEO of Voip-Pal (OTCQB: VPLM), a Bellevue, Washington based company, inventers and pioneers of the switching technology now being used by many of the world's largest telecommunication and social networking companies, without which they could not connect Landline phone calls to Internet phone calls.

Mr. Malak has many other business ventures and is well versed on the coronavirus pandemic and its possible spread. Mr. Malak explained that, “We must treat COVID-19 like other killer diseases, such as cancer, heart problems, diabetes, pulmonary issues, and lupus etc.” However, Mr. Malak points to out that the major difference in this disease is that it has managed to hide, as it is asymptomatic and now it is crippling our economies. He says, “Asymptomatic: patients do not show any clinical symptoms, have normal chest imaging, but yield a positive nucleic acid test. They become silent, invisible, and lethal vectors of COVID-19, being just as likely to spread the virus as a symptomatic patient. Children are more likely to be asymptomatic carriers of COVID-19 than adults. It is believed that between 10% to 15% or more of carriers are asymptomatic. It only takes one to infect dozens, hundreds or even thousands of people in an enclosed environment.”

Since we seem to be in a global war, and every country would need a marshal plan in order to get back their economies. When asked what a marshal plan to combat the coronavirus should look like, Mr. Malak responded, “The Coronavirus Marshal Plan begins with executing the right testing strategy. Mobile testing vans need to be deployed and visible in every community. Once a person is tested, their current test results would be displayed on their smartphone. As long a person tests negative, they could move about freely. Anyone who tests positive can receive early treatment and isolate themselves to avoid spreading the virus to their family and friends, and avoid mass spreading within the community.

Only testing everyone continuously is the solution according to Mr. Malak, “Tests should be repeated on a weekly basis to ensure each person has an accurate current result. This provides the only safe way forward. By implementing this coronavirus Marshal Plan we will be able to fully reopen the economy without worrying about a surge of new infections or increased mortality rates. Businesses will be positioned to soar once again to their pre-COVID-19 heights. Testing frequencies can always be reviewed and adjusted as needed.”

As to what we would need to do to get international air travel back to normal, Mr. Malak responds, “In my proposal, airlines would provide testing to each passenger no longer than 48 hours before boarding the plane. In some instances, they can even offer the test at the airport. Only passengers with a negative test result would be permitted to board the plane. A passenger would take the test prior to their outbound flight and again before their return flight. Requiring each passenger to show a current negative test result before boarding will restore confidence in the safety of air travel.”

Is China the new evil empire requiring everyone to cut trade with them? Mr. Malak told CEOCFO's Bud Wayne, “The people who make up the silent majority in the United States and Europe realize that China has not been truthful. They can see through the lies and how China has benefited economically from the coronavirus pandemic while the rest of the world suffers greatly – the Chinese regime is laughing all the way to the bank! It is time for the world’s leaders to come together and stop all dealings with the Chinese government. China must suffer consequences for the pain and suffering they have unleashed on the world. Additionally, severing ties with the Chinese will create millions and millions of jobs outside of China and help countries once again become self-sufficient. This is no time for globalization or bowing to the interests of the World Trade Organization (WTO) that has shown so much bias in favor of the Chinese and has helped spread the Chinatization of much of the world.”

Bud Wayne
CEOCFO Magazine
+1 570-851-1745
email us here

Source: EIN Presswire

U.S. Rep. Grace Meng Issues Resolution Recognizing National Period Poverty Awareness Week, May 25 – 31, 2020

The Alliance for Period Supplies created Period Poverty Awareness Week to educate on the issue period poverty and the impact period poverty has on menstruators.

Alliance for Period Supplies logo

The Alliance for Period Supplies works to address period poverty in the U.S.

National Period Poverty Awareness Week is a signature event of the Alliance for Period Supplies—a program of the National Diaper Bank Network.

Period poverty is a public health issue that largely goes unnoticed in the U.S. This is unacceptable.”

— Joanne Goldblum, CEO National Diaper Bank Network

NEW HAVEN, CT, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Prior to the COVID-19 pandemic, 1 in 4 U.S. women struggled to afford period supplies in the past year. This public health issue, known as period poverty, has increased exponentially since the crisis began.

To draw attention to period poverty, U.S. Rep. Grace Meng (D-NY), today, issued a resolution formally recognizing National Period Poverty Awareness Week (May 25 – 31, 2020) and Menstrual Hygiene Day (May 28, 2020) in the U.S.

National Period Poverty Awareness Week is a signature event of the Alliance for Period Supplies—a program of the National Diaper Bank Network. This is the first year of the event which is being celebrated throughout the country.

“Period poverty is a public health issue that largely goes unnoticed in the U.S.,” said Joanne Goldblum, CEO of the National Diaper Bank Network and Alliance for Period Supplies. “Rep. Meng’s resolution recognizing National Period Poverty Awareness Week draws attention to the fact that there are menstruators living in each of communities who cannot afford these basic necessities. This is unacceptable. We applaud Rep. Meng for her leadership and advocacy efforts on behalf of all people who menstruate.”

With the support if its founding sponsor U by Kotex®, the Alliance for Period Supplies has distributed more than 30 million donated period products to its more than 80 allied programs nationwide that provide free period products to menstruators who lack the material basic necessities they require to thrive.

Through its advocacy efforts, the Alliance for Period Supplies worked with Rep. Ming to secure the resolution. It recognizes the contributions of individuals and entities that operate or support period supply banks and distribution programs in their local communities, prior to and in response to the COVID–19 pandemic, as well as the generosity of the people of the United States for supporting those struggling with period poverty by donating menstrual products.

About Alliance for Period Supplies

The Alliance for Period Supplies is an initiative of the National Diaper Bank Network (NDBN)—a 501(c)(3) nonprofit organization that leads a nationwide movement aimed at helping individuals and families who struggle to afford material basic needs. Launched in May 2018, with the support of founding sponsor U by Kotex, the Alliance for Period Supplies works to end period poverty (#endperiodpoverty) in the US by raising national awareness of the issue and supporting the development and expansion of period supply programs in communities throughout the country. The Alliance for Period Supplies is comprised of Allied Programs that collect, warehouse and distribute menstrual/period supplies in local communities. More information on Alliance for Period Supplies is available at allianceforperiodsupplies.org, and on Twitter (@PeriodSupplies) and Facebook (facebook.com/AllianceForPeriodSupplies).

Troy Moore
+1 860-216-3034
email us here

Source: EIN Presswire

David Tutera, Celebrity Wedding & Event Expert Designs, Plans & Officates the Virtual Wedding of the Year

A front-line responder, a hero, surprised by David Tutera, as he sets to bring her Dream Wedding to LIFE

Creating celebrations is NOT a job to me, it’s my passion… I simply love what I do!”

— David Tutera

MALIBU, CA, USA, May 28, 2020 /EINPresswire.com/ — During these challenging and unprecedented times, Leading Wedding & Entertaining Expert, David Tutera is inspired to bring JOY and to shed LIGHT, LOVE and to continue to create special LIFE MOMENTS when we need it most. David will surprise, design and officiate the wedding of one lucky couple ~ Andrea & Ethan ~ making their dream come true. This couple, unfortunately was not able to move forward with their original plans; but David will stop at nothing to bring this special moment to LIFE.

The Mother-of-the-Bride, Wanda Minken, a long-time follower of David, reached out to share details about her daughter, Andrea, a Connecticut Physician Assistant, working 65-80 hours a week in the Intensive Care Unit treating Covid-19 patients. Andrea gets up every morning at 4:30am to prepare for another day in the trenches, not returning home until after 7:30pm. “Every day is a physical and emotional drain, shares Wanda, “but Andrea is a kind and compassionate young woman that treats all of her patients and families with dignity and grace, especially in these most desperate times.” She is known to many as "A Warrior in Scrubs"!

Although her spirit is broken, and she is disappointed that she has had to postpone her wedding, Andrea believes her wedding is trivial compared to what is happening around her. This is where David comes in!

David will surprise the couple LIVE…and continue the process of planning, designing and executing the vision of their dream wedding…LIVE. “Creating celebrations is NOT a job to me, it’s my passion…I simply love what I do!”, says David. From planning to execution to providing all the elements they need, David and his team will work closely with the amazing partners he has brought together, to make sure that this special couple gets the wedding ceremony of their dreams, on the exact date of their original wedding, June 27, 2020.

To bring this Virtual Wedding of the Year to life, David is partnering with PartySlate, a photo-rich platform that inspires people planning events and connects them with the leading event professionals and venues across the country and the world; and a host of other amazing partners including Butterfly Florals, Dogwood Blossom Stationery, Stitch & Tie by Friar Tux and Impressive Creations.

David’s true goal is always to make the bride & groom feel like a guest at their own celebration and to always create an “EXPERIENCE” for all who attend. A dream can become a reality with the expertise of David Tutera and team, whether it’s in person or virtual. A feel good story is what the world needs right now! David Tutera is the perfect person to bring this Celebration and Special Moment to LIFE!

David Tutera, entertaining expert, event designer, motivational speaker, TV personality, fashion designer, lifestyle brand and author, is hailed as an artistic visionary whose ability, uniquely creative talents and passion for designing has made him a tremendous success in the event and lifestyle arena. David's specialty is creating one of a kind celebrations that truly represent the honoree(s). It is through the details in every aspect of an event that an event can be the perfect medium to tell the perfect celebration story.

David's award winning, full-service, domestic and global brand is built from experience, dedication and his natural talent for transforming the ordinary into the extraordinary. David began his career in party planning more than thirty years ago, and today, he continues to create magic and make dreams come true. David measures his success by being a father of two beautiful girls, Cielo and Gracie and loving husband to Joey.

PartySlate is a photo-rich platform that inspires people planning events and connects them with the leading event professionals and venues across the country and the world.

Since its founding in 2015, PartySlate has acquired 10,000 of the world’s top event professionals and venues who have uploaded more than 750,000 beautiful event photos to the website. PartySlate is headquartered in Chicago and has launched in 17 cities.

Lisa Newberry
Dada Media, Inc., dba David Tutera
+1 310-570-7611
email us here
Visit us on social media:

Source: EIN Presswire

Research at MDI Biological Laboratory Explores Novel Pathways of Regeneration and Tumorigenesis

Dustin Updike, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine

Dustin Updike's research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent.”

— Hermann Haller, M.D, president, MDI Biological Laboratory

BAR HARBOR, MAINE, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Research by scientists at the MDI Biological Laboratory in Bar Harbor, Maine, is opening up new approaches to promoting tissue regeneration in organs damaged by disease or injury.

In recent years, research in regenerative biology has focused on stem cell therapies that reprogram the body’s own cells to replace damaged tissue, which is a complicated process because it involves turning genes in the cell’s nucleus on and off.

A recent paper in the journal Genetics by MDI Biological Laboratory scientist Elisabeth Marnik, Ph.D., a postdoctoral fellow in the laboratory of Dustin Updike, Ph.D., offers insight into an alternate pathway to regeneration: by recreating the properties of germ cells.

Germ cells, which are the precursors to the sperm and egg, are considered immortal because they are the only cells in the body with the potential to create an entirely new organism. The stem cell-like ability of germ cells to turn into any type of cell is called “totipotency.”

“By getting a handle on what makes germ cells totipotent, we can promote regeneration by unlocking the stem cell-like properties of other cell types,” said Updike. “Our research shows that such cells can be reprogrammed by manipulating their cytoplasmic composition and chemistry, which would seem to be safer and easier than changing the DNA within a cell’s nucleus.”

Using the tiny, soil-dwelling nematode worm, C. elegans, as a model, the Updike lab studies organelles called germ granules that reside in the cytoplasm (the contents of the cell outside of the nucleus) of germ cells. These organelles, which are conserved from nematodes to humans, are one of the keys to the remarkable attributes of germ cells, including the ability to differentiate into other types of cells.

In their recent paper entitled “Germline Maintenance Through the Multifaceted Activities of GLH/Vasa in Caenorhabditis elegans P Granules,” Updike and his team describe the “intriguing and elusive” role of “Vasa” proteins within germ granules in determining whether a cell is destined to become a germ cell with totipotent capabilities or a specific type of cell, like those that comprise muscle, nerves or skin.

Because of the role of Vasa proteins in preserving totipotency, an increased understanding of how such proteins work could lead to unprecedented approaches to de-differentiating cell types to promote regeneration; or alternatively, to new methods to turn off totipotency when it is no longer desirable, as in the case of cancer.

“The increase in chronic and degenerative diseases caused by the aging of the population is driving demand for new therapies,” said MDI Biological Laboratory President Hermann Haller, M.D. “Dustin’s research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent, as well as an increased understanding of cancer.”

Because of the complexity of the cellular chemistry, research on Vasa and other proteins found in germ granules is often overlooked, but that is rapidly changing — especially among pharmaceutical companies — as more scientists realize the “impact and potential” of such research, not only for regenerative medicine but also for an understanding of tumorigenesis, or cancer development, Updike said.

Recent research has found that some cancers are accompanied by the mis-expression of germ granule proteins, which are normally found only in germ cells. The mis-expression of these germ-granule proteins seems to promote the immortal properties of germ cells, and consequently tumorigenesis, with some germ-granule proteins now serving as prognosis markers for different types of cancer, Updike said.

Updike is a former postdoctoral researcher in the laboratory of Susan Strome, Ph.D., at University of California, Santa Cruz. Strome, who was inducted into the National Academy of Sciences last year, first discovered P granules more than 30 years ago. She credits Updike, who has published several seminal papers on the subject, with “great imagination, determination and excellent technical skill” in the pursuit of his goal of elucidating the function and biochemistry of these tiny organelles.

The lead author of the new study from the Updike laboratory, Elisabeth A. Marnik, Ph.D., will be launching her own laboratory at Husson University in Bangor, Maine, this fall. Other contributors include J. Heath Fuqua, Catherine S. Sharp, Jesse D. Rochester, Emily L. Xu and Sarah E. Holbrook. Their research was conducted at the Kathryn W. Davis Center for Regenerative Biology and Medicine at the MDI Biological Laboratory.

Updike’s research is supported by a grant (R01 GM-113933) from the National Institute of General Medical Sciences (NIGMS), an institute of the National Institutes of Health (NIH). The equipment and cores used for part of the study were supported by NIGMS-NIH Centers of Biomedical Research Excellence and IDeA Networks of Biomedical Research Excellence grants P20 GM-104318 and P20 GM-203423, respectively.

About the MDI Biological Laboratory

We aim to improve human health and healthspan by uncovering basic mechanisms of tissue repair, aging and regeneration, translating our discoveries for the benefit of society and developing the next generation of scientific leaders. For more information, please visit mdibl.org.

Stefanie Matteson
MDI Biological Laboratory
+1 201-787-7427
email us here

Source: EIN Presswire

Impact of COVID-19 on Global Contraceptives Drugs and Devices Market 2020 Trend, Segmentation and Forecast to 2026

New Study Reports "Contraceptives Drugs and Devices Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026" has been Added.

PUNE, MAHARASHTRA, INDIA, May 29, 2020 /EINPresswire.com/ — Contraceptives Drugs and Devices Market 2020-2026

New Study Reports "Contraceptives Drugs and Devices Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026" has been Added on WiseGuyReports.

Introduction/Report Summary:

This report provides in depth study of “Contraceptives Drugs and Devices Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Contraceptives Drugs and Devices Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

Contraceptives are birth spacing products that aid in avoiding unwanted/ unplanned pregnancy. There are five widely used contraceptive methods namely barrier method, hormonal method, emergency contraception, intrauterine method, and sterilization. Women can opt for wide range of contraceptive options such as vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects.

Drivers and Constraints

The fundamental dynamics that are explored in the report hold substantial influence over the Contraceptives Drugs and Devices market. The report further studies on the value, volume trends, and the pricing history of the market. In addition to it, various growth factors, restraints, and opportunities are also analyzed for the market to study the in-depth understanding of the market.

This report also analyzes the impact of Coronavirus COVID-19 on the Contraceptives Drugs and Devices industry.

Key Players

The report has profiled some of the Important players prevalent in the global like – Teva Pharmaceutical Industries Ltd, Church & Dwight Co. Inc, Reckitt Benckiser Plc, Pfizer, Inc, Bayer AG, Mayer Laboratories, Inc, The Female Health Company, Cooper Surgical, Inc, Allergan plc, Cipla Limited, Merck & Co. Inc, and more.

This report covers the sales volume, price, revenue, gross margin, manufacturers, suppliers, distributors, intermediaries, customers, historical growth and future perspectives in the Contraceptives Drugs and Devices.

Request for Free Sample Report of “Contraceptives Drugs and Devices” Market @  https://www.wiseguyreports.com/sample-request/5337844-covid-19-impact-on-contraceptives-drugs-and-devices

Market Segmentation based On Type, Application and Region:

The global Contraceptives Drugs and Devices is analyzed for different segments to arrive at an insightful analysis. Such segmentation has been done based on type, application, and region.

Based on Type, the global Contraceptives Drugs and Devices Market is segmented into Contraceptive Drugs (Oral Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives), Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices) and other

Based on Application, the Contraceptives Drugs and Devices Market is segmented into Female, Male, and Others.

Based on Detailed Regional Analysis, the regional segmentation has been carried out for regions of U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America. The report on WGR includes an in-depth study of the Contraceptives Drugs and Devices in each regional segment mentioned above.

Key Stakeholders 
Contraceptives Drugs and Devices Market Manufacturers 
Contraceptives Drugs and Devices Market Distributors/Traders/Wholesalers 
Contraceptives Drugs and Devices Market Subcomponent Manufacturers 
Industry Association 
Downstream Vendors

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@ https://www.wiseguyreports.com/reports/5337844-covid-19-impact-on-contraceptives-drugs-and-devices

Major Key Points from Table of Content:

1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Contraceptives Drugs and Devices Industry
1.7 COVID-19 Impact: Contraceptives Drugs and Devices Market Trends

7 Company Profiles
7.1 Teva Pharmaceutical Industries Ltd
7.1.1 Teva Pharmaceutical Industries Ltd Business Overview
7.1.2 Teva Pharmaceutical Industries Ltd Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.1.3 Teva Pharmaceutical Industries Ltd Contraceptives Drugs and Devices Product Introduction
7.1.4 Teva Pharmaceutical Industries Ltd Response to COVID-19 and Related Developments
7.2 Church & Dwight Co. Inc
7.2.1 Church & Dwight Co. Inc Business Overview
7.2.2 Church & Dwight Co. Inc Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.2.3 Church & Dwight Co. Inc Contraceptives Drugs and Devices Product Introduction
7.2.4 Church & Dwight Co. Inc Response to COVID-19 and Related Developments
7.3 Reckitt Benckiser Plc
7.3.1 Reckitt Benckiser Plc Business Overview
7.3.2 Reckitt Benckiser Plc Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.3.3 Reckitt Benckiser Plc Contraceptives Drugs and Devices Product Introduction
7.3.4 Reckitt Benckiser Plc Response to COVID-19 and Related Developments
7.4 Pfizer, Inc
7.4.1 Pfizer, Inc Business Overview
7.4.2 Pfizer, Inc Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.4.3 Pfizer, Inc Contraceptives Drugs and Devices Product Introduction
7.4.4 Pfizer, Inc Response to COVID-19 and Related Developments

and more

Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.


+1 646-845-9349
email us here

Source: EIN Presswire

Transvaginal Mesh Litigation: A Focused Look at Compensatory Damages Post-MDL

Women with disabling injuries have yet to settle claims against TVM manufacturers because accepting the offer would result in living as a medical indigent.

I have talked to women injured by Ethicon and Boston Scientific… destroyed by pudendal neuralgia, and offered pennies on the dollar by tier settlements that did nothing to prevent medical indigence.”

— Dr. Greg Vigna

SANTA BARBARA, CA, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Within the rubble of the West Virginia Transvaginal Mesh Multidistrict Litigation (MDL) are likely a few hundred or so brave women with disabling injuries who have yet to settle their claims against the manufacturers because accepting the offered compensation under the tier settlements would have punched their ticket to a life-time living as a medical indigent. Many within the rubble have symptoms or diagnoses consistent with neurological injuries caused by the defectively designed products of Bard, American Medical Systems, Ethicon, Coloplast, and Boston Scientific. Many are disabled and alone; some divorced; and most struggling week to week to gather the basic necessities of life.

Dr. Greg Vigna, national pharmaceutical injury attorney, practicing physicians, and Certified Life Care Planner says, “June 21, 2018 was a very important date for the women holding on within the MDL because it signaled the time that seriously injured women could have their cases directly filed in courts outside the MDL and have a clear path to the courthouse without being stuck in the MDL. It signaled the time when serious trial attorneys could step up and litigate these cases.”

Dr. Vigna states, “I have talked to women over the years injured by Ethicon and Boston Scientific, with their deep pockets, destroyed by pudendal neuralgia, and offered pennies on the dollar by tier settlements that did nothing to prevent their medical indigence. The MDL was about erosion and not about neurological injury. Since the MDL closed its doors to new cases, my law firm with co-counsel of experienced pharmaceutical trial attorneys were the first to file a newly injured women diagnosed with pudendal neuralgia in California, and we have since filed dozens of cases for seriously injured women across the country.”

Dr. Vigna adds, “We represent women in the ‘wave’ discovery process of the MDL, women remanded to state courts from the MDL, and women who are subject to a tolling agreement after their case was dismissed without prejudice in the MDL. These women will be marched to the courthouse while we work up their cases for trial.”

Martin Baughman, PLLC from Dallas Texas, a national pharmaceutical injury trial firm, has filed many of these cases. Ben Martin, Esq. states, “The purpose of product liability law is injury reduction and compensation. Looking at the serious injuries of the women I represent, it is obvious that the manufacturers to date haven’t owned up to the harm they have caused.”

Mr. Martin adds, “We are carefully investigating cases to ensure that women who have neurological injuries who are severely harmed are represented.”

Compensatory damages in a product injury lawsuit include past and future losses along with payment for their pain and suffering. Past losses include those from vocational disability and cost of medical care, as well as future monetary losses including the cost of necessary and appropriate care. Vocational loss and future care require evidence—sometimes presented by vocational and economic experts and life care planners.

Ben Martin and Laura Baughman are national pharmaceutical injury attorneys in Dallas, Texas. Dr. Vigna is a California and Washington DC lawyer who focuses on catastrophic injuries caused by transvaginal mesh devices including pudendal neuralgia, obturator neuralgia, ilioinguinal neuralgia, and Complex Regional Pain Syndrome.

For articles, video resources, and information visit the Pudendal Neuralgia Educational Portal (https://pudendalportal.lifecare123.com/) or https://tvm.lifecare123.com/.

Click here for information regarding sling related complications: https://tvm.lifecare123.com/slingebook.html
Click here for a FREE BOOK on Vaginal Mesh Pain: https://vignalawgroup.com/publications/

Greg Vigna, MD, JD
Vigna Law Group
1155 Coast Village Rd., Suite 3, Santa Barbara, CA

Greg Vigna
Greg Vigna, M.D., J.D., PLC
+1 800-761-9206
email us here
Visit us on social media:

Source: EIN Presswire

ShowStoppers® TV features Energous, HyperX, Jabra, MYHIXEL, Xandar Kardian healthtech in broadcast to journalists

ShowStoppers® TV features healthtech from Energous, HyperX, Jabra, MYHIXEL, Xandar Kardian in press conference broadcast to journalists worldwide

AUSTIN, TX, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Today’s online broadcast of ShowStoppers® TV, http://www.showstoppers.com, featured four companies with tools, products and healthtech for wellness – connecting Energous, HyperX, Jabra, MYHIXEL and Xandar Kardian with technology and business journalists around the globe.

Creating the first series of showcase events on the digital screen as a new platform for multiple companies to launch products and services, meet the press, and generate coverage, the ShowStoppers TV broadcast episodes are online editions of the in-person press events that ShowStoppers organizes at CES, IFA, Mobile World Congress, CEATEC, NAB Show and other tradeshows around the world.

Journalists from 31 countries registered in advance to attend the one-hour broadcast, organized as a virtual press conference. Each company presented for ten minutes, with questions moderated by Helena Stone, editor in chief of Geekspin.co, http://www.geekspin.co; entrepreneur, founder and former editor of Chip Chick, which grew to be the top tech site for women; featured on MSNBC, Wired, ABC News, People, Time Magazine, Women's Day and other major news outlets. At the end of the broadcast, each company was provided a private virtual meeting room to continue the conversation with specific questions from journalists.

Energous, http://www.energous.com, showed “its latest WattUp wireless charging technology, as well as its recently announced WattUp PowerHub solution, specifically focusing on wireless charging for health/medical IoT applications such as fitness bands, smartwatches, hearables, smart glasses, medical devices and more,” said Gordon Bell, vice president, marketing.

HyperX, www.hypergaming.com, a division of Kingston Technology Inc., announced new eyewear for parents and children gaming at home, and for parents working from home in front of a computer screen for hours. “The new HyperX eyewear is designed to be comfortable even while wearing a gaming headset. It filters out the blue light that is known to cause fatigue or eyestrain,” said Mark Tekunoff, corporate public relations manager.

“Summer is here, and whether you’re heading outside to run, bike, hike, or to take a walk – Jabra’s Elite Active 75t true wireless earbuds are your perfect outdoor activity companion. The earbuds offer a small and lightweight design for all-day, secure and comfortable wear and have a battery life of 7.5 hours on a single charge – with an extra two charges in the case. You can easily pair the earbuds with your devices to stream your favorite playlists; they’re waterproof and sweat-and-dust-resistant,” said Adam Robertson, director of product marketing at Jabra, www.jabra.com.

“MYHIXEL is a medical innovator presenting a revolutionary male sexual health solution,” said Dominnique Karetsos, https://myhixel.com. “MYHIXEL is the first medically proven gamification Play App + Device that guarantees next-level pleasure, designed specifically to achieve climax control.”

“None of us know when we will have a vaccine for COVID19,” said David Kim, chief financial and strategy officer, Xandar Kardian, http://www.xkcorp.com. “But Xandar Kardian’s vital sign sensor provides continuous, non-contact, autonomous, real-time monitoring of patient conditions and well-being. XK’s proprietary solution helps Long-Term-Care facilities increase staff efficiency, particularly so at a time when staffing shortages are a major concern for healthcare service providers.”

About ShowStoppers TV

ShowStoppers TV premiered 2 Apr. 2020 as a new online broadcast edition of the industry-leading in-person events that ShowStoppers produces around the world.

“We know how challenging it is now to do business, to make a difference,” said Dave Leon, partner, ShowStoppers. “We believe ShowStoppers TV builds on our extensive event production experience to create showcase events on the digital screen that help multiple companies connect with journalists globally in order to launch new products and services that cope with today’s new realities.”

About ShowStoppers

Now in its 25th year, ShowStoppers, http://www.showstoppers.com/, is the global leader in producing press and business events spanning the U.S., Europe and Asia. Each event organizes product launches, sneak previews and demonstrations for selected journalists, bloggers, industry and financial analysts, venture capitalists and business executives. Industry leaders, innovators and startups exhibit to generate news coverage and product reviews, make new connections, promote brand and open new markets.

ShowStoppers produces official press events at CES, CE Week, IFA and NAB; partners with MWC and CEATEC; and produces events during CES and other tradeshows.

To sign up to meet the press at ShowStoppers press events online at ShowStoppers TV and in-person around the world, contact Lauren Merel, mailto:lauren@showstoppers.com, +1 908-692-6068.

Steven Leon
+1 3109368530
email us here

Source: EIN Presswire

AACR Integrates with Code Ocean

This is an example of a Code Ocean compute capsule associated to a article published in Cancer Research in

Code Ocean compute capsule associated to an article published in Cancer Research

American Association for Cancer Research Journals Integrate Code Ocean to Help Improve Research Reproducibility

NEW YORK, NY, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Code Ocean, a computational reproducibility platform, is pleased to announce that the American Association for Cancer Research (AACR), the largest professional organization related to cancer research, will integrate Code Ocean into the AACR journals platform.

Code Ocean enables authors to share fully functional and executable code accompanying their articles and to allow readers to re-run the analysis in the cloud and reproduce the results, bypassing the need to install the software. Authors upload their software code, with either test or actual raw data, to the Code Ocean online software environment. Code Ocean then verifies the code and, once the article is published, allows others to easily run, edit, and reuse the code from any web browser.

“The integration of Code Ocean into the journal platform will increase the impact of the AACR journals by allowing researchers to deposit their code and data essential to reproducing research results,” said Christine Battle, Publisher and Vice President, Scientific Publications at the AACR. “The mission of all AACR journals is to publish robust, hypothesis-driven science in order to further our knowledge of cancer while promoting rigor and reproducibility.”

“It is an honor to be working with the AACR, a leader in cancer research. The integration of Code Ocean into the AACR journals platform furthers our mission to make computational research easier, more collaborative, and durable. Computational biology and bioinformatics are fast becoming a critical area of importance and are a focus for Code Ocean as funders’ requirements demand more transparency.” said Simon Adar, CEO and Co-founder of Code Ocean.

The AACR will deploy Code Ocean across all nine of the AACR journals on May 21, 2020. Within the manuscript submission process via the AACR’s implementation of the EJPress online submission and peer review system authors will be invited to submit their code, creating an efficient way to associate these first-class research objects with their manuscript. Upon publication of the code, Code Ocean generates a citable Digital Object Identifier (DOI) to increase author attribution of code as part of their publication record; reviewers and other readers of the submitted manuscript will be able reproduce for themselves, using the Code Ocean online software environment, the computational analyses reported by the authors in their manuscript.

The full press release can be found here


The AACR is the largest professional organization dedicated to advancing cancer research and its mission to prevent and cure all cancers. The organization was founded in 1907, and its membership includes more than 47,000 laboratory, translational, and clinical researchers; population scientists; other healthcare professionals; and patient advocates residing in 127 countries.


Code Ocean is a cloud-based computational reproducibility platform that provides researchers in academia and biopharma with an easy way to develop, share, and run code. Code Ocean streamlines computational research with an integrated management platform so researchers can start projects (called compute capsules) faster, can collaborate easily and don't have to worry about computing resources. Once published, compute capsules are preserved for reproducibility, data provenance and reuse.

Pierre Montagano
Code Ocean
+1 215-460-8344
email us here
Visit us on social media:

Source: EIN Presswire

Dr. David Samadi: VA testing prostate cancer drug on male veterans with COVID-19

Testosterone could be a risk factor for Covid-19

men treated for advanced prostate cancer and had lower testosterone, had lower chance of getting Covid-19

relationship of testosterone and Covid-19

Covid-19 needs a protein to enter your lung system called TMPRSS2. Just like Lock and Key. Testosterone seem to be activating this protein hence more prone.

Men on hormonal treatment for advanced prostate cancer, low testosterone had four fold lower chance of getting Covid-19. Testosterone can activate the protein that the virus needs to enter our system.”

— Dr. David Samadi

NEW YORK, NEW YORK, UNITED STATES, May 28, 2020 /EINPresswire.com/ — A clinical trial to investigate the potential of treating men with COVID-19 will soon begin by the Department of Veterans Affairs (VA) to study the use of degarelix, a drug approved by the FDA for prostate cancer. The West Los Angeles VA Medical Center will lead the clinical trial but also included will be VA medical centers in Manhattan and Brooklyn in New York, and Washington State. The VA trial is expected to be completed within four months.
“I applaud the VA in their innovation to look at this medication for the possible treatment of COVID-19,” stated Dr. David Samadi, Director of Men’s Health and Urologic Oncology at St. Francis Hospital at Roslyn, New York. “The more knowledge we can collect with the hope of finding that breakthrough drug that can conquer this virus, the better for all of us.”
The VA announced that the study will include almost 200 male veterans hospitalized with COVID-19. It will be a double-blind, randomized controlled trial comparing degarelix to a placebo.
“Degarelix, also known as Firmagon, is a treatment for advanced hormone dependent prostate cancer and works by decreasing the amount of testosterone produced by the body,” explained Dr. Samadi. “The hormone testosterone can fuel the growth of prostate cancer so this medication temporarily suppresses the body’s production of this hormone with the intent of slowing or stopping the spread of prostate cancer. The researchers with this study believe that if testosterone levels are lowered temporarily, then this might prevent the virus from infiltrating lung cells.”
So far what is known about COVID-19, is the short- and long-term effects it has on lung health for some people. Lung complications can include pneumonia and in more severe cases, acute respiratory distress syndrome (ARDS), along with sepsis, a complication that can cause lasting harm to the lungs and other organs.
Research has suggested that testosterone may be triggering the production of a protein called TMPRSS2 on lung tissue. This protein is believed to be what COVID-19 uses to invade lung tissue. Veterans who receive the drug as part of the clinical trial will only be given one dose of Degarelix that lasts for 28 days.
Women veterans will not be included in this study as this medication could make things worse for them by having the opposite effect of increasing the protein the virus needs to enter the lungs and increasing the severity of COVID-19 symptoms.
Dr. Samadi commented that there can be side effects from Degarelix that the male veterans might experience. These include hot flashes, weight gain, increased sweating along with night sweats, back and joint pain, and fatigue. However, the side effects should be temporary and once the treatment is done, testosterone levels will go back to normal.
“This will be a very interesting study to see what the results will reveal,” exclaimed Dr. Samadi. “It is encouraging and exciting to learn about the numerous clinical trials being conducted throughout the world with the aim of finding an effective treatment for COVID-19. We will find one and if it’s this prostate cancer drug, that’s even better.”

Dr. David Samadi is the Director of Men’s Health and Urologic Oncology at St. Francis Hospital in Long Island. He’s a renowned and highly successful board certified Urologic Oncologist Expert and Robotic Surgeon in New York City, regarded as one of the leading prostate surgeons in the U.S., with a vast expertise in prostate cancer treatment and Robotic-Assisted Laparoscopic Prostatectomy. Visit Dr. Samadi’s websites at robotic oncology and prostate cancer 911.

Dr. David Samadi, M.D.
+1 212-365-5000
email us here

Source: EIN Presswire